Clinical Trials Logo
  1. Home
  2. Discoid Lupus Erythematosus
  3. NCT00608673

Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus

Discoid Lupus Erythematosus Clinical Trial

Official title:
Pimecrolimus 1% Cream vs. Betamethasone Valerate 0.1% Cream in the Treatment of Facial Discoid Lupus Erythematosus: a Double-Blind Randomized, Pilot Study.

Clinical Trial Summary

Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but corticosteroids may induce side effects such as thinning of the skin or scarring. Therefore, an alternative medication with the same efficacy, but without the side-effects is sought after.

Pimecrolimus is a newer drug specially designed to treat inflammatory diseases of skin. Its efficacy in treating discoid lupus erythematosus has not been studied extensively yet. However studies performed till now show promising results. Long-term topical use of this medication has not shown any serious side-effects in other skin diseases.

In this study we aimed at comparing pimecrolimus efficacy with that of a common therapeutic choice, betamethasone valerate 0.1% cream, to see if pimecrolimus can be used as an alternative medication in treating discoid lupus erythematosus.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00608673
Study type Interventional
Source hahid Beheshti University of Medical Sciences
Contact
Status Completed
Phase N/A
Start date April 2006
Completion date November 2007
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT03866317 - A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus Phase 2
Completed NCT00001680 - A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Phase 2
Recruiting NCT05591222 - Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus Phase 2
Completed NCT00625521 - Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions Phase 2
Completed NCT04908280 - Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus Phase 2
Completed NCT02125695 - Pilot Tape Harvesting Study N/A
Completed NCT05362188 - Topical Nicotinamide in Treatment of DLE Early Phase 1
Completed NCT00708916 - Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Phase 1/Phase 2
Terminated NCT03958955 - Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus. Phase 2
Terminated NCT03159936 - Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Early Phase 1
Completed NCT00691769 - Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
Recruiting NCT06261021 - Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus Phase 2
Completed NCT00625157 - Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) Phase 2